Immunocore (IMCR) Projected to Announce Earnings on Thursday

Immunocore (NASDAQ:IMCR) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $148.3160 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. The company had revenue of $106.68 million for the quarter, compared to the consensus estimate of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. Immunocore’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 EPS. On average, analysts expect Immunocore to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Immunocore Stock Up 2.5%

Shares of IMCR stock opened at $33.24 on Wednesday. The stock has a market cap of $1.69 billion, a P/E ratio of -60.44 and a beta of 0.74. Immunocore has a 52 week low of $27.56 and a 52 week high of $40.71. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The company’s fifty day simple moving average is $31.33 and its two-hundred day simple moving average is $31.32.

Analyst Ratings Changes

IMCR has been the topic of several research reports. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Monday, April 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Mizuho increased their target price on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday. Finally, Zacks Research lowered shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Immunocore presently has a consensus rating of “Hold” and a consensus price target of $56.29.

Institutional Investors Weigh In On Immunocore

Several large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC raised its position in Immunocore by 334.3% during the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock valued at $45,993,000 after purchasing an additional 974,463 shares during the period. Vestal Point Capital LP purchased a new position in shares of Immunocore in the 4th quarter worth approximately $20,305,000. Janus Henderson Group PLC bought a new position in shares of Immunocore during the 4th quarter valued at approximately $15,734,000. Bellevue Group AG increased its position in shares of Immunocore by 14.5% during the 3rd quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after purchasing an additional 354,973 shares during the last quarter. Finally, Tang Capital Management LLC raised its holdings in Immunocore by 14.0% during the 4th quarter. Tang Capital Management LLC now owns 2,628,538 shares of the company’s stock valued at $91,237,000 after buying an additional 322,930 shares during the period. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.